Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract 1377: Endogenous antibodies recognize multiple proteins on B78 melanoma in mice cured via immunotherapy

Anna Hoefges, Sean J. McIlwain, Amy K. Erbe, Trang Q. Le, Kaitlin Tetreault, Nicholas Mathers, Alexander L. Rakhmilevich, Jacquelyn A. Hank, Jigar Patel, Brad Garcia, Zachary S. Morris, Irene M. Ong, Paul M. Sondel

Cancer Res (2022) 82 (12_Supplement): 1377.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1377

Published: 15 June 2022

View article

Journal Articles

Abstract 4055: Immune checkpoint DNA vaccines enhance anti-tumor immunity in murine melanoma model

Keng-Hsueh Lan, Raghava Sriramaneni, Justin C. Jagodinsky, Claire Baniel, Amy Erbe-Gurel, Jacquelyn A. Hank, Sung-Hsin Kuo, Keng-Li Lan, Zachary S. Morris

Cancer Res (2020) 80 (16_Supplement): 4055.

DOI: https://doi.org/10.1158/1538-7445.AM2020-4055

Published: 15 August 2020

View article

Journal Articles

Abstract LB-048: Impact of KIR/KIR ligand genotype for neuroblastoma patients in a Phase 3 COG immunotherapy trial

Amy K. Erbe, Wei Wang, Lakeesha Carmichael, KyungMann Kim, Patrick K. Reville, Wendy B. London, Jacquelyn A. Hank, Mitchell B. Diccianni, Arlene Naranjo, Michael Hogarty, Julie R. Park, Alice L. Yu, Paul M. Sondel

Cancer Res (2017) 77 (13_Supplement): LB-048.

DOI: https://doi.org/10.1158/1538-7445.AM2017-LB-048

Published: 01 July 2017

View article

Journal Articles

Abstract 4011: Effective in situ immunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody

Zachary S. Morris, Emily Guy, David Francis, Monica M. Gressett, Eric A. Armstrong, Shyhmin Huang, Lauryn R. Werner, Stephen D. Gillies, Alan Korman, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel

Cancer Res (2016) 76 (14_Supplement): 4011.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4011

Published: 15 July 2016

View article

Journal Articles

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

Zachary S. Morris, Emily I. Guy, David M. Francis, Monica M. Gressett, Lauryn R. Werner, Lakeesha L. Carmichael, Richard K. Yang, Eric A. Armstrong, Shyhmin Huang, Fariba Navid, Stephen D. Gillies, Alan Korman, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel

Cancer Res (2016) 76 (13): 3929–3941.

DOI: https://doi.org/10.1158/0008-5472.CAN-15-2644

Published: 30 June 2016

View article

Includes: Supplementary data

Journal Articles

Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma

Cindy L. Zuleger, Paul M. Sondel, Jacquelyn A. Hank, Erik A. Ranheim, Thomas A. McFarland, Jennifer Collins, Erin Clements, Giles Whalen, Uri Galili, Mark R. Albertini

Cancer Res (2014) 74 (19_Supplement): 2538.

DOI: https://doi.org/10.1158/1538-7445.AM2014-2538

Published: 01 October 2014

View article

Journal Articles

Abstract 1538: Enhanced antitumor effects of intratumoral (IT) hu14.18-IL2 immunocytokine (IC) compared to intravenous (IV) hu14.18-IL2 are distinguished by increased activated tumor infiltrating lymphocytes (TILs) and IC retention

Richard K. Yang, Nicholas A. Kalogriopoulos, Alexander L. Rakhmilevich, Erik A. Ranheim, Songwon Seo, KyungMann Kim, Kory L. Alderson, Jacek Gan, Ralph A. Reisfeld, Stephen D. Gillies, Jacquelyn A. Hank, Paul M. Sondel

Cancer Res (2012) 72 (8_Supplement): 1538.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1538

Published: 15 April 2012

View article

Journal Articles

Abstract 1809: Stimulation of antibody dependent cell-mediated cytotoxicity by interleukin-15 is equivalent to interleukin-2

Kimberly A. McDowell, Jacquelyn A. Hank, Paul M. Sondel

Cancer Res (2011) 71 (8_Supplement): 1809.

DOI: https://doi.org/10.1158/1538-7445.AM2011-1809

Published: 15 April 2011

View article

Journal Articles

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

David C. Delgado, Jacquelyn A. Hank, Jill Kolesar, David Lorentzen, Jacek Gan, Songwon Seo, KyungMann Kim, Suzanne Shusterman, Stephen D. Gillies, Ralph A. Reisfeld, Richard Yang, Brian Gadbaw, Kenneth B. DeSantes, Wendy B. London, Robert C. Seeger, John M. Maris, Paul M. Sondel

Cancer Res (2010) 70 (23): 9554–9561.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-2211

Published: 06 December 2010

View article

Journal Articles

Abstract LB-325: Antitumor effect of resveratrol combined with immunocytokine immunotherapy

Brenda L. Soto, Jacquelyn A. Hank, Arthur S. Polans, Tyler van de Voort, Alexander L. Rakhmilevich, Songwon Seo, Kim Kuyungmann, Stephen D. Gillies, Paul M. Sondel

Cancer Res (2010) 70 (8_Supplement): LB-325.

DOI: https://doi.org/10.1158/1538-7445.AM10-LB-325

Published: 15 April 2010

View article

Journal Articles

The functional effects of anti-hu14.18 antibody activity found in the serum of patients following IV infusion of immunocytokine (IC) hu14.18-IL2 for treatment of melanoma

Jacquelyn A. Hank, Michael Stauder, Adam Sternberg, Michael Kagan, Jacek Gan, Mark Albertini, K. M. Lo, Stephen Gillies, Paul M. Sondel

Cancer Res (2005) 65 (9_Supplement): 166.

Published: 01 May 2005

View article

Journal Articles

Augmentation of Antibody Dependent Cell Mediated Cytotoxicity following in Vivo Therapy with Recombinant Interleukin 2

Jacquelyn A. Hank, Randy R. Robinson, Jean Surfus, Barbara M. Mueller, Ralph A. Reisfeld, Nai-Kong Cheung, Paul M. Sondel

Cancer Res (1990) 50 (17): 5234–5239.

Published: 01 September 1990

View article

Journal Articles

Natural Killer Cells Activated by Interleukin 2 Treatment in Vivo Respond to Interleukin 2 Primarily through the p75 Receptor and Maintain the p55 (TAC) Negative Phenotype

Gilda Weil-Hillman, Stephan D. Voss, Paul Fisch, Kathleen Schell, Jacquelyn A. Hank, Jeffrey A. Sosman, Kazuo Sugamura, Paul M. Sondel

Cancer Res (1990) 50 (9): 2683–2691.

Published: 01 May 1990

View article

Journal Articles

Lymphokine-activated Killer Activity Induced by in Vivo Interleukin 2 Therapy: Predominant Role for Lymphocytes with Increased Expression of CD2 and Leu19 Antigens but Negative Expression of CD16 Antigens

Gilda Weil-Hillman, Paul Fisch, Audrey F. Prieve, Jeffrey A. Sosman, Jacquelyn A. Hank, Paul M. Sondel

Cancer Res (1989) 49 (13): 3680–3688.

Published: 01 July 1989

View article

Journal Articles

Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer

Paul M. Sondel, Peter C. Kohler, Jacquelyn A. Hank, Karen H. Moore, Nancy S. Rosenthal, Jeff A. Sosman, Robin Bechhofer, Barry Storer

Cancer Res (1988) 48 (9): 2561–2567.

Published: 01 May 1988

View article

Journal Articles

In Vivo Induction of the Lymphokine-activated Killer Phenomenon: Interleukin 2-dependent Human Non-Major Histocompatibility Complex-restricted Cytotoxicity Generated in Vivo during Administration of Human Recombinant Interleukin 2

Jacquelyn A. Hank, Peter C. Kohler, Gilda Weil-Hillman, Nancy Rosenthal, Karen H. Moore, Barry Storer, Debbie Minkoff, Jeff Bradshaw, Robin Bechhofer, Paul M. Sondel

Cancer Res (1988) 48 (7): 1965–1971.

Published: 01 April 1988

View article

Journal Articles

In Vitro Analysis of Donor Bone Marrow following Monoclonal Antibody Treatment for the Prevention of Acute Graft versus Host Disease

Peter C. Kohler, Christene Erickson, Johnathan L. Finlay, Michael E. Trigg, Bruce Edwards, Richard Hong, Jacquelyn A. Hank, Ronald Billing, Marek Bozdech, Paul M. Sondel

Cancer Res (1986) 46 (10): 5413–5418.

Published: 01 October 1986

View article

NARROW

Abstract 1377: Endogenous antibodies recognize multiple proteins on B78 melanoma in mice cured via immunotherapy

Abstract 4055: Immune checkpoint DNA vaccines enhance anti-tumor immunity in murine melanoma model

Abstract LB-048: Impact of KIR/KIR ligand genotype for neuroblastoma patients in a Phase 3 COG immunotherapy trial

Abstract 4011: Effective in situ immunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma

Abstract 1538: Enhanced antitumor effects of intratumoral (IT) hu14.18-IL2 immunocytokine (IC) compared to intravenous (IV) hu14.18-IL2 are distinguished by increased activated tumor infiltrating lymphocytes (TILs) and IC retention

Abstract 1809: Stimulation of antibody dependent cell-mediated cytotoxicity by interleukin-15 is equivalent to interleukin-2

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

Abstract LB-325: Antitumor effect of resveratrol combined with immunocytokine immunotherapy

The functional effects of anti-hu14.18 antibody activity found in the serum of patients following IV infusion of immunocytokine (IC) hu14.18-IL2 for treatment of melanoma

Augmentation of Antibody Dependent Cell Mediated Cytotoxicity following in Vivo Therapy with Recombinant Interleukin 2

Natural Killer Cells Activated by Interleukin 2 Treatment in Vivo Respond to Interleukin 2 Primarily through the p75 Receptor and Maintain the p55 (TAC) Negative Phenotype

Lymphokine-activated Killer Activity Induced by in Vivo Interleukin 2 Therapy: Predominant Role for Lymphocytes with Increased Expression of CD2 and Leu19 Antigens but Negative Expression of CD16 Antigens

Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer

In Vivo Induction of the Lymphokine-activated Killer Phenomenon: Interleukin 2-dependent Human Non-Major Histocompatibility Complex-restricted Cytotoxicity Generated in Vivo during Administration of Human Recombinant Interleukin 2

In Vitro Analysis of Donor Bone Marrow following Monoclonal Antibody Treatment for the Prevention of Acute Graft versus Host Disease

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only